The National Institutes of Health and Kalypsys, Diosynth Biotechnology and Selexis, TekCel and Biophile, and Iconix Pharmaceuticals and Icos, Taisho Pharmaceuticals, and AstraZeneca | GenomeWeb

NIH Taps Kalypsys Screening Technology

The National Institutes of Health will use screening technology from Kalypsys at its newly created NIH Chemical Genomics Center, the company said earlier this month.

The agreement, which was announced on June 9, is worth up to $30 million, according to San Diego-based Kalypsys. The Chemical Genomics Center, based at the National Human Genome Research Institute, will use Kalypsys’ high-throughput screening technology to produce chemical tools to help understand the function of the genome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.